Accuray Appoints Paul Miele as Senior VP and Chief Commercial Officer
- Accuray appoints Paul Miele as Senior Vice President and Chief Commercial Officer.
- Miele's role aims to improve Accuray's commercial performance.
- The appointment focuses on enhancing execution within the company.
Accuray Incorporated announces the appointment of Paul Miele as Senior Vice President and Chief Commercial Officer, effective April 6, 2026. This strategic decision aims to bolster the company's commercial performance amid an evolving healthcare landscape. Miele joins Accuray equipped with nearly two decades of experience in the medical technology sector, holding notable leadership roles that align with the company's objectives for growth.
A Proven Leader in Medical Technology
Prior to joining Accuray, Miele served as the Business Unit Leader for the MONARCH™ robotic platform at Johnson & Johnson MedTech, where his initiatives reversed a trend of declining revenues, achieving a significant turnaround that resulted in double-digit sales growth. His extensive background also includes pivotal roles at Globus Medical and Intuitive Surgical, where he earned a reputation as a change agent in commercial operations, thereby enhancing business performance and customer engagement.
Strategic Vision for Global Commercialization
In his new role, Miele is tasked with defining and executing Accuray's global commercialization strategies, which encompass sales, pricing, and market access. Emphasizing the importance of innovation, he acknowledges Accuray's established presence in over 70 countries, focusing on enhancing sales of the company's state-of-the-art radiation therapy systems and services. Miele is committed to advancing the mission of improving patient lives through leading-edge solutions in cancer treatment.
Commitment to Improved Patient Care
Miele's appointment at Accuray reflects the company's intention to stay at the forefront of medical technology and patient care. His background not only enhances the leadership team but also reinforces Accuray's commitment to delivering innovative radiation therapy solutions beneficial to patients globally. With a keen focus on commercialization, Miele’s leadership is expected to drive growth and optimize operations, ultimately aiming to improve outcomes for cancer patients.
Overall, Miele's entry into Accuray's executive team marks a significant step towards reinforcing the company's position in the radiation therapy industry, as it strives to enhance its commercial strategy while remaining dedicated to patient care.